Sweating the small stuff: MicroRNAs and genetic changes define pancreatic cancer

Pancreas

Volumn 42, Issue 5, 2013, Pages 740-759

  Tang, Siuwah ^a   Bonaroti, Jillian ^b   Unlu, Sebnem ^b   Liang, Xiaoyan ^b   Tang, Daolin ^b   Zeh, Herbert J ^b   Lotze, Michael T ^a,b  

^a University of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Biomarker; Circulating; Genetic mutation; MicroRNA (miRNA); Pancreatic cancer

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MICRORNA; MICRORNA 200; MICRORNA 21; MICRORNA 55; PROTEIN P53; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG;

CANCER GENETICS; CARCINOGENESIS; CELL CYCLE; DNA REPAIR; EPIGENETICS; GENE MUTATION; METASTASIS; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; TUMOR INVASION;

EARLY DIAGNOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS; MUTATION; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84880080446     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182854ab0     Document Type: Review

References (271)

1. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7(3):211-217.
2. Locker GY, Hamilton S, Harris J., et al ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313-5327.
3. Liu NK, Xu XM MicroRNA in central nervous system trauma and degenerative disorders. Physiol Genomics. 2011:1;43(10):571-580.
4. Yu J, Liu F, Yin P., et al Integrating miRNA and mRNA expression profiles in response to heat stress-induced injury in rat small intestine. Funct Integr Genomics. 2011:11(2):203-213.
5. Simone NL, Soule BP, Ly D, et al Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One. 2009;4(7):e6377.
6. Babar IA, Slack FJ, Weidhaas JB MiRNA modulation of the cellular stress response. Future Oncol. 2008;4(2):289-298.
7. Olson P, Lu J, Zhang H., et al MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009;23(18):2152-2165.
8. Keller A, Leidinger P, Borries A., et al MiRNAs in lung cancerVstudying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer. 2009;9:353.
9. Tian Y, Luo A, Cai Y., et al MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem. 2010:285(11):7986-7994.
10. Hausler SF, Keller A, Chandran P.A., et al Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer. 2010;103(5):693-700.
11. Li A, Omura N, Hong S.M., et al Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010;70(13):5226-5237.
12. Wang J, Chen J, Chang P., et al MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009;2(9):807-813.
13. Tsujiura M, Ichikawa D, Komatsu S., et al Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010;102(7):1174-1179.
14. Tanaka M, Oikawa K, Takanashi M., et al Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One. 2009;4(5):e5532.
15. Liu CJ, Kao SY, Tu H.F., et al Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010;16(4):360-364.
16. Hu Z, Chen X, Zhao Y., et al Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28(10):1721-1726.
17. Huang Z, Huang D, Ni S., et al Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127(1):118-126.
18. Leidinger P, Keller A, Borries A., et al High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer. 2010;10:262.
19. Gonzales JC, Fink LM, Goodman OB Jr, et al Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 2011;9(1):39-45.
20. Zhao S, Liu MF Mechanisms of microRNA-mediated gene regulation. Sci China C Life Sci. 2009;52(12):1111-1116.
21. Thermann R, Hentze MW Drosophila miR2 induces pseudo-polysomes and inhibits translation initiation. Nature. 2007;447(7146):875-878.
22. Mathonnet G, Fabian MR, Svitkin Y.V., et al MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science. 2007;317(5845):1764-1767.
23. Kiriakidou M, Tan GS, Lamprinaki S, et al An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell. 2007;129(6):1141-1151.
24. Wakiyama M, Takimoto K, Ohara O et al. Let-7 microRNAYmediated mRNA deadenylation and translational repression in a mammalian cell-free system. Genes Dev. 2007;21(15):1857-1862.
25. Petersen CP, Bordeleau ME, Pelletier J, et al Short RNAs repress translation after initiation in mammalian cells. Mol Cell. 2006;21(4):533-542.
26. Cenik ES, Zamore PD Argonaute proteins. Curr Biol. 2011;21(12):R446-R449.
27. Ghildiyal M, Zamore PD Small silencing RNAs: an expanding universe. Nat Rev Genet. 2009;10(2):94-108.
28. Tolia NH, Joshua-Tor L. Slicer and the argonautes. Nat Chem Biol. 2007;3(1):36-43.
29. Parker R, Sheth U. P bodies and the control of mRNA translation and degradation. Mol Cell. 2007;25(5):635-646.
30. Sen GL, Blau HM Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies. Nat Cell Biol. 2005;7(6):633-636.
31. Liu J, Valencia-Sanchez MA, Hannon G.J., et al MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol. 2005;7(7):719-723.
32. Anderson P, Kedersha N. RNA granules. J Cell Biol. 2006;172(6):803-808.
33. Cortez MA, Calin GA MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009;9(6):703-711.
34. Wang K, Yuan Y, Cho J.H., et al Comparing the microRNA spectrum between serum and plasma. PLoS One. 2012;7(7):e41561.
35. Sisco KL. Is RNA in serum bound to nucleoprotein complexes? Clin Chem. 2001;47(9):1744-1745.
36. El-Hefnawy T., Raja S, Kelly L., et al Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004;50(3):564-573.
37. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13-21.
38. Resnick KE, Alder H, Hagan J.P., et al The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009;112(1):55-59.
39. Skog J, Wurdinger T, van Rijn S, et al Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470-1476.
40. Rabinowits G, Gercel-Taylor C, Day J.M., et al Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009;10(1):42-46.
41. Zhang Y, Li M, Wang H., et al Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 2009;33(4):698-709.
42. Jamieson NB, Morran DC, Morton J.P., et al MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res. 2012;18(2):534-545.
43. Zhang XJ, Ye H, Zeng C.W., et al Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol. 2010;3:46.
44. Szafranska AE, Davison TS, John J, et al MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26(30):4442-4452.
45. Volinia S, Calin GA, Liu C.G., et al A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257-2261.
46. Kang R, Loux T, Tang D., et al The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A. 2012;109(18):7031-7036.
47. Lee EJ, Gusev Y, Jiang J., et al Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120(5):1046-1054.
48. Habbe N, Koorstra JB, Mendell J.T., et al MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 2009;8(4):340-346.
49. Dillhoff M, Liu J, Frankel W., et al MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008;12(12):2171-2176.
50. Kong X, Du Y, Wang G., et al Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 2011;56(2):602-609.
51. Ohuchida K, Mizumoto K, Kayashima T., et al MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol. 2011;18(8):2381-2387.
52. Li Y, Vanden Boom TG 2nd, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69(16):6704-6712.
53. Hwang JH, Voortman J, Giovannetti E., et al Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One. 2010;5(5):e10630.
54. Morimura R, Komatsu S, Ichikawa D., et al Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer. 2011;105(11):1733-1740.
55. Xu X, Gnatenko DV, Ju J, et al Systematic analysis of microRNA fingerprints in thrombocythemic platelets using integrated platforms. Blood. 2012;120(17):3575-3585
56. Hayat MJ, Howlader N, Reichman M.E., et al Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20-37.
57. Yamaguchi K, Enjoji M, Tsuneyoshi M. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol. 1991;47(3):148-154.
58. Papaconstantinou IG, Manta A, Gazouli M., et al Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 2013;42(1):67-71.
59. Saito M, Schetter AJ, Mollerup S, et al The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res. 2011;17(7):1875-1882
60. Nagao Y, Hisaoka M, Matsuyama A., et al Association of microRNA-21 expression with its targets, PDCD4, TIMP3, in pancreatic ductal adenocarcinoma. Mod Pathol. 2012:112-121.
61. Merline R, Moreth K, Beckmann J., et al Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and microRNA-21. Sci Signal. 2011;4(199):ra75.
62. Zhu S, Wu H, Wu F., et al MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008;18(3):350-359.
63. Si ML, Zhu S, Wu H., et al MiR-21Ymediated tumor growth. Oncogene. 2007;26(19):2799-2803.
64. Giovannetti E, Funel N, Peters G.J., et al MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010:4528-4538.
65. Bao B, Ali S, Kong D., et al Anti-tumor activity of a novel compound YCDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLos ONE. 2011:1-11.
66. Xu J, Wu C, Che X., et al Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50(2):136-142.
67. Bhattacharyya S, Siegel ER, Petersen G.M., et al Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia. 2004;6(5):674-686.
68. Shibuya H, Iinuma H, Shimada R., et al Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 2010;79(3-4):313-320.
69. Jiang S, Zhang HW, Lu M.H., et al MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010;70(8):3119-3127.
70. Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens. 2006;67(1):1-9.
71. Tang B, Xiao B, Liu Z., et al Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. FEBS Lett. 584(8):1481-1486.
72. Gironella M, Seux M, Xie M.J., et al Tumor protein 53Yinduced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007;104(41):16170- 16175.
73. O'Connell R.M., Rao DS, Chaudhuri A.A., et al Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med. 2008;205(3):585-594.
74. Metcalf D, Dakic A, Mifsud S., et al Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103(5):1486-1491.
75. Fulci V, Chiaretti S, Goldoni M., et al Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 2007;109(11):4944-4951.
76. He H, Jazdzewski K, Li W., et al The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005;102(52):19075-19080.
77. Yan LX, Huang XF, Shao Q, et al MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14(11):2348-2360.
78. Iorio MV, Ferracin M, Liu C.G., et al MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065-7070.
79. Nikiforova MN, Tseng GC, Steward D, et al MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008;93(5):1600-1608.
80. Wang X, Tang S, Le S.Y., et al Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 2008;3(7):e2557.
81. Jay C, Nemunaitis J, Chen P., et al MiRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007;26(5):293-300.
82. Yanaihara N, Caplen N, Bowman E., et al Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189-198.
83. Pallante P, Visone R, Ferracin M., et al MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006;13(2):497-508.
84. Faraoni I, Antonetti FR, Cardone J, et al miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta. 2009;1792(6):497-505.
85. Masaki S, Ohtsuka R, Abe Y., et al Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem Biophys Res Commun. 2007;364(3):509-514.
86. Stanczyk J, Pedrioli DM, Brentano F, et al Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008;58(4):1001-1009.
87. Taganov KD, Boldin MP, Chang K.J., et al NF-kappaBYdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006;103(33):12481-12486.
88. O'Connell R.M., Taganov KD, Boldin M.P., et al MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A. 2007;104(5):1604-1609.
89. hai TH, Calado DP, Casola S, et al Regulation of the germinal center response by microRNA-155. Science. 2007;316(5824):604-608.
90. Martin MM, Lee EJ, Buckenberger J.A., et al MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem. 2006;281(27):18277-18284.
91. Martin MM, Buckenberger JA, Jiang J, et al The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem. 2007;282(33):24262-24269.
92. Gottwein E, Mukherjee N, Sachse C., et al Aviral microRNA functions as an orthologue of cellular miR-155. Nature. 2007;450(7172):1096-1099.
93. Skalsky RL, Samols MA, Plaisance K.B., et al Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol. 2007;81(23):12836-12845.
94. Donnem T, Eklo K, Berg T., et al Prognostic impact of miR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med. 2011;9:6.
95. Wang F, Zheng Z, Guo J., et al Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 119;(3):586-593.
96. Yu J, Ohuchida K, Mizumoto K., et al MicroRNA, hsa-miR-200c is, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Molecular Cancer. 2010:1-10.
97. Li Y, VandenBoom TG II, Kong D, et al Up-regulation of miR-200 and let-7 by natural agents lead to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009:6704-6712.
98. Miyoshi T, Maruhashi M, Van De Putte T, et al. Complementary expression pattern of Zfhx1 genes Sip1 and deltaEF1 in the mouse embryo and their genetic interaction revealed by compound mutants. Dev Dyn. 2006;235(7):1941-1952.
99. Lu J, Getz G, Miska E.A., et al MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838.
100. Baskerville S, Bartel DP Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA. 2005;11(3):241-247.
101. Yang H, Kong W, He L., et al MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68(2):425-433.
102. Nam EJ, Yoon H, Kim S.W., et al MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008;14(9):2690-2695.
103. Iorio MV, Visone R, Di Leva G, et al MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67(18):8699-8707.
104. Nakada C, Matsuura K, Tsukamoto Y., et al Genome-wide microRNA expression profiling in renal cell carcinoma: significant downregulation of miR-141 and miR-200c. J Pathol. 2008;216(4):418-427.
105. Ladeiro Y, Couchy G, Balabaud C., et al MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008;47(6):1955-1963.
106. Nakajima G, Hayashi K, Xi Y., et al Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics. 2006;3(5):317-324.
107. Leskela S, Leandro-Garcia LJ, Mendiola M., et al The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer. 2011;18(1):85-95.
108. Kasinski AL, Slack FJ MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11(12):849-864.
109. Costinean S, Zanesi N, Pekarsky Y., et al PreYB cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006;103(18):7024-7029.
110. O'Connell R.M., Kahn D, Gibson W.S., et al MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010;33(4):607-619.
111. Rodriguez A, Vigorito E, Clare S., et al Requirement of bic/ microRNA-155 for normal immune function. Science. 2007;316(5824):608-611.
112. Hatley ME, Patrick DM, Garcia M.R., et al Modulation of Kras-dependent lung tumorigenesis by microRNA-21. Cancer Cell. 2010;18(3):282-293.
113. Chan JA, Krichevsky AM, Kosik KS MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65(14):6029-6033.
114. Ma X, Kumar M, Choudhury S.N., et al Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci U S A. 2011;108(25):10144-10149.
115. Gibbons DL, Lin W, Creighton C.J., et al Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009;23(18):2140-2151.
116. Samuel N, Hudson TJ The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;9(2):77-87.
117. Truty MJ, Urrutia R. Transforming growth factor-beta: what every pancreatic surgeon should know. Surgery. 2007;141(1):1-6.
118. Yeo TP, Hruban RH, Leach S.D., et al Pancreatic cancer. Curr Probl Cancer. 2002;26(4):176-275.
119. Hahn SA, Hoque AT, Moskaluk C.A., et al Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996;56(3):490-494.
120. Hahn SA, Schutte M, Hoque A.T., et al DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271(5247):350-353.
121. Furukawa T, Sunamura M, Horii A. Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci. 2006;97(1):1-7.
122. Levy L, Hill CS SMAD4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol. 2005;25(18):8108-8125.
123. Dogar AM, Towbin H, Hall J. Suppression of latent transforming growth factor (TGF)-beta1 restores growth inhibitory TGF-beta signaling through microRNAs. J Biol Chem. 2010;286(18):16447-16458.
124. Martello G, Zacchigna L, Inui M., et al MicroRNA control of nodal signalling. Nature. 2007;449(7159):183-188.
125. Yao G, Yin M, Lian J., et al MicroRNA-224 is involved in transforming growth factor-beta-mediated mouse granulosa cell proliferation and granulosa cell function by targeting SMAD4. Mol Endocrinol. 2010,24(3):540-551.
126. Petrocca F, Visone R, Onelli M.R., et al E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13(3):272-286.
127. Wang B, Hsu SH, Majumder S, et al TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene. 2010;29(12):1787-1797.
128. Mestdagh P, Bostrom AK, Impens F, et al The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell. 2010;40(5):762-773.
129. Dews M, Fox JL, Hultine S, et al The myc-miR-17-92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res. 2010;70(20):8233-8246.
130. Chan MC, Hilyard AC, Wu C, et al Molecular basis for antagonism between PDGF and the TGFbeta family of signalling pathways by control of miR-24 expression. EMBO J. 2010;29(3):559-573.
131. Davis BN, Hilyard AC, Lagna G, et al SMAD proteins control Drosha-mediated microRNA maturation. Nature. 2008;454(7200):56-61.
132. Gregory PA, Bracken CP, Smith E, et al An autocrine TGF-beta/ZEB/ miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell. 2011; 22(10):1686-1698.
133. Kong W, Yang H, He L., et al MicroRNA-155 is regulated by the transforming growth factor beta/SMAD pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28(22):6773-6784.
134. Morris JP I.V., Wang SC, Hebrok M. Kras, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10(10):683-695.
135. Aguirre AJ, Bardeesy N, Sinha M., et al Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17(24):3112-3126.
136. Hingorani SR, Petricoin EF, Maitra A, et al Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437-450.
137. Zampetaki A, Kiechl S, Drozdov I., et al Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107(6):810-817.
138. Sharifah NA, Nurismah MI, Lee H.C., et al Identification of novel large genomic rearrangements at the BRCA1 locus in Malaysian women with breast cancer. Cancer Epidemiol. 2010;34(4):442-447.
139. Jemal A, Siegel R, Xu J., et al Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
140. Carriere C, Seeley ES, Goetze T, et al The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A. 2007;104(11):4437-4442.
141. Hingorani SR, Wang L, Multani A.S., et al Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469-483.
142. Morelli MP, Kopetz S. Hurdles and complexities of codon 13 Kras mutations. J Clin Oncol. 2012;30(29):3565-3567.
143. Stefanius K, Ylitalo L, Tuomisto A., et al Frequent mutations of Kras in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology. 2011;58(5):679-692.
144. Kent OA, Chivukula RR, Mullendore M, et al Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feedforward pathway. Genes Dev. 2010;24(24):2754-2759.
145. Zhao WG, Yu SN, Lu Z.H., et al The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting Kras. Carcinogenesis. 2010;31(10):1726-1733.
146. Yu S, Lu Z, Liu C., et al MiRNA-96 suppresses Kras and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010;70(14):6015-6025.
147. Sureban SM, May R, Lightfoot S.A., et al DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 2011;71(6):2328-2338.
148. Rothfuss A, Grompe M. Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol Cell Biol. 2004;24(1):123-134.
149. Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene. 2002;21(58):8981-8993.
150. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med. 2002;8(12):571-576.
151. Morton JP, Steele CW, Sansom OJ Timing is everything: BRCA2 and p53 mutations in pancreatic cancer. Gastroenterology. 2011;140(4):1143-1146. 152.
152. Rowley M, Ohashi A, Mondal G., et al Inactivation of BRCA2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology. 2011;140(4):1303-1313, e1301-e1303.
153. James E, Waldron-Lynch MG, Saif MW. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs. 2009;20(7):634-638.
154. Edwards SL, Brough R, Lord C.J., et al Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451(7182):1111-1115.
155. Shen J, Ambrosone CB, DiCioccio R.A., et al A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis. 2008;29(10):1963-1966.
156. Lee CH, Subramanian S, Beck A.H., et al MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One. 2009;4(10):e7314.
157. Chang S, Wang RH, Akagi K, et al Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med. 2011;17(10):1275-1282
158. Levine AJ, Finlay CA, Hinds PW p53 Is a tumor suppressor gene. Cell. 2004;116(2 suppl):S67-S69, 61p following S69.
159. Levine AJ, Hu W, Feng Z. The p53 pathway: what questions remain to be explored? Cell Death Differ. 2006;13(6):1027-1036.
160. Lehmann BD, Pietenpol JA Targeting mutant p53 in human tumors. J Clin Oncol. 2012;30(29):3648-3650.
161. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413-431.
162. Suzuki HI, Miyazono K. Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med (Berl). 2011;88(11):1085-1094.
163. Livesey KM, Kang R, Vernon P., et al p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res. 2012;72(8):1996-2005.
164. Feng Z, Zhang C, Wu R., et al Tumor suppressor p53 meets microRNAs. J Mol Cell Biol. 2011;3(1):44-50.
165. Yokoyama M, Yamanaka Y, Friess H., et al p53 Expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res. 1994;14(6B):2477-2483.
166. Costentin L, Pages P, Bouisson M., et al Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases. Pancreatology. 2002;2(1):17-25.
167. Tsutsumi M, Tsujiuchi T, Ishikawa O., et al Increased telomerase activities in human pancreatic duct adenocarcinomas. Jpn J Cancer Res. 1997;88(10):971-976.
168. Suzuki HI, Yamagata K, Sugimoto K., et al Modulation of microRNA processing by p53. Nature. 2009;460(7254):529-533.
169. Fukuda T, Yamagata K, Fujiyama S., et al DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat Cell Biol. 2007;9(5):604-611.
170. Tanner NK, Linder P. DExD/H box RNA helicases: from generic motors to specific dissociation functions. Mol Cell. 2001;8(2):251-262.
171. Bates GJ, Nicol SM, Wilson B.J., et al The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J. 2005;24(3):543-553.
172. Iacobuzio-Donahue C.A., Maitra A, Shen-Ong GL, et al Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol. 2002;160(4):1239-1249.
173. Hustinx SR, Leoni LM, Yeo C.J., et al Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol. 2005;18(7):959-963.
174. Hruban RH, Goggins M, Parsons J., et al Progression model for pancreatic cancer. Clin Cancer Res. 2000;6(8):2969-2972.
175. Ohtsubo K, Watanabe H, Yamaguchi Y., et al Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters. J Gastroenterol. 2003;38(7):663-671.
176. Fleming JB, Shen GL, Holloway S.E., et al Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res. 2005;3(7):413-423.
177. Whelan AJ, Bartsch D, Goodfellow PJ Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med. 1995;333(15):975-977.
178. Chien WW, Domenech C, Catallo R., et al Cyclin-dependent kinase 1 expression is inhibited by p16(INK4a) at the post-transcriptional level through the microRNA pathway. Oncogene. 2011;30(16):1880-1891.
179. Vurusaner B, Poli G, Basaga H. Tumor suppressor genes and ROS: complex networks of interactions. Free Radic Biol Med. 2012;52(1):7-18.
180. Gabriely G, Yi M, Narayan R.S., et al Human glioma growth is controlled by microRNA-10b. Cancer Res. 2011;71(10):3563-3572.
181. Poliseno L, Pitto L, Simili M., et al The proto-oncogene LRF is under post-transcriptional control of miR-20a: implications for senescence. PLoS One. 2008;3(7):e2542.
182. Whitcomb DC. Inflammation and cancer. V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 2004;287(2):G315- G319.
183. Tang D, Kang R, Zeh HJ 3rd, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010;1799(1-2):131-140.
184. Sparvero LJ, Asafu-Adjei D, Kang R., et al RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009;7:17.
185. Lotze MT, Tracey KJ High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5(4):331-342.
186. Muller S, Scaffidi P, Degryse B., et al New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 2001;20(16):4337-4340.
187. Ellerman JE, Brown CK, de Vera M, et al Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13(10):2836-2848.
188. Dong Xda E., Ito N, Lotze M.T., et al High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother. 2007;30(6):596-606.
189. Scaffidi P, Misteli T, Bianchi ME Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191-195.
190. Leclerc E, Fritz G, Weibel M., et al S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem. 2007;282(43):31317-31331.
191. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med. 2007;7(8):711-724.
192. Schenk S, Schraml P, Bendik I., et al A novel polymorphism in the promoter of the RAGE gene is associated with non-small cell lung cancer. Lung Cancer. 2001;32(1):7-12.
193. Carlsson H, Petersson S, Enerback C. Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development. Int J Oncol. 2005;27(6):1473-1481.
194. Shanmugam N, Reddy MA, Natarajan R. Distinct roles of heterogeneous nuclear ribonuclear protein K and microRNA-16 in cyclooxygenase-2 RNA stability induced by S100b, a ligand of the receptor for advanced glycation end products. J Biol Chem. 2008;283(52):36221-36233.
195. Xia L, Zhang D, Du R., et al miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123(2):372-379.
196. Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006;43(1):1-67.
197. Drakos E, Singh RR, Rassidakis G.Z., et al Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Leukemia. 2011;25(5):856-867.
198. Unlu S, Tang S, Wang E., et al Damage associated molecular pattern molecule-induced microRNAs (DAMPmiRs) in human peripheral blood mononuclear cells. PLoS One. 2012;7(6):e38899.
199. He L, He X, Lim L.P., et al A microRNA component of the p53 tumour suppressor network. Nature. 2007;447(7148):1130-1134.
200. Yamakuchi M, Ferlito M, Lowenstein CJ MiR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A. 2008;105(36):13421-13426.
201. Li X, Zhang Y, Shi Y., et al MicroRNA-107, an oncogene microRNA that regulates tumor invasion and metastasis by targeting DICER1 in gastric cancer. J Cell Mol Med. 2011;15(9):1887-1895.
202. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17(2):193-199.
203. Iliou MS, Lujambio A, Portela A., et al Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer. Epigenetics. 2011;6(11):1344-1353.
204. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-714.
205. Hanoun N, Delpu Y, Suriawinata A.A., et al The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem. 2010;56(7):1107-1118.
206. Lee KH, Lotterman C, Karikari C., et al Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology. 2009;9(3):293-301.
207. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57-63.
208. Nagalakshmi U, Wang Z, Waern K., et al The transcriptional landscape of the yeast genome defined by RNA sequencing. Science. 2008;320(5881):1344-1349.
209. Mortazavi A, Williams BA, McCue K, et al Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5(7):621-628.
210. Cloonan N, Forrest AR, Kolle G, et al Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat Methods. 2008;5(7):613-619.
211. Seila AC, Calabrese JM, Levine S.S., et al Divergent transcription from active promoters. Science. 2008;322(5909):1849-1851.
212. Taft RJ, Glazov EA, Cloonan N, et al Tiny RNAs associated with transcription start sites in animals. Nat Genet. 2009;41(5):572-578.
213. Watahiki A, Wang Y, Morris J., et al MicroRNAs associated with metastatic prostate cancer. PLoS One. 2011;6(9):e24950.
214. Chen PS, Su JLCha ST, et al miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. J Clin Invest. 2011;121(9):3442-3455.
215. Mattia G, Errico MC, Felicetti F, et al Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma. Pigment Cell Melanoma Res. 2011;24(5):953-965.
216. Zhang JG, Wang JJ, Zhao F, et al MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010;411(11-12):846-852.
217. Zhang Y, Gao JS, Tang X, et al MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett. 2009;583(22):3725-3730.
218. Gregory PA, Bert AG, Paterson E.L., et al The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593-601.
219. Jazbutyte V, Thum T. MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets. 2010;11(8):926-935.
220. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep. 2010;11(9):670-677.
221. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene. 1999;18(19):2967-2987.
222. Papaconstantinou IG, Manta A, Gazouli M., et al Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 2013;42(1):67-71
223. Bloomston M, Frankel WL, Petrocca F, et al MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297(17):1901-1908.
224. 1 arrest and inhibits invasion in gastric cancer cells. Med Oncol.
225. Yamakuchi M, Lotterman CD, Bao C, et al p53-Induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A. 2010;107(14):6334-6339.
226. Seux M, Peuget S, Montero M.P., et al TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression. Oncogene. 2011;30(27):3049-3061.
227. Eis PS, Tam W, Sun L., et al Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005;102(10):3627-3632.
228. Pekarsky Y, Santanam U, Cimmino A., et al Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006;66(24):11590-11593.
229. Zheng C, Yinghao S, Li J. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Med Oncol. 2012;29(2):815-822.
230. Lu C, Huang X, Zhang X., et al MiR-221 and miR-155 regulate human dendritic cell development, apoptosis and IL-12 production through targeting of p27kip1, KPC1 and SOCS-1. Blood. 2011;117(16):42923-303.
231. Fornari F, Gramantieri L, Ferracin M., et al MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008;27(43):5651-5661.
232. Garofalo M, Di Leva G, Romano G, et al miR-221 & 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16(6):498-509.
233. Lu X, Zhao P, Zhang C., et al Analysis of miR-221 and p27 expression in human gliomas. Mol Med Report. 2009;2(4):651-656.
234. Cimmino A, Calin GA, Fabbri M, et al miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102(39):13944-13949.
235. Ofir M, Hacohen D, Ginsberg D. MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res. 2011;9(4):440-447.
236. Asangani IA, Rasheed SA, Nikolova D.A., et al MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27(15):2128-2136.
237. Fassan M, Pizzi M, Giacomelli L., et al PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis. Virchows Arch. 2011;458(4):413-419.
238. Frankel LB, Christoffersen NR, Jacobsen A, et al Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008;283(2): 1026-1033.
239. Qi L, Bart J, Tan L.P., et al Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9:163.
240. Bai H, Xu R, Cao Z., et al Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 2011;585(2):402-408.
241. Zhou M, Liu Z, Zhao Y., et al MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic BCL-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 2010;285(28):21496-21507.
242. Zhao WY, Wang DD, Song M.Q., et al Role of microRNA-223 and its target gene oncogene c-Myc in hepatocellular carcinoma pathogenesis. Zhonghua Gan Zang Bing Za Zhi. 2011;19(2):114-117.
243. Li S, Li Z, Guo F., et al miR-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma. J Biomed Sci. 2011;18(1):24.
244. Sun W, Shen W, Yang S., et al miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-beta. Cell Res. 2010;20(10):1158-1169.
245. Luna C, Li G, Qiu J., et al MicroRNA-24 regulates the processing of latent TGFbeta1 during cyclic mechanical stress in human trabecular meshwork cells through direct targeting of FURIN. J Cell Physiol. 2011;226(5):1407-1414.
246. Liu X, Wang A, Heidbreder C.E., et al MicroRNA-24 targeting RNA-binding protein DND1 in tongue squamous cell carcinoma. FEBS Lett. 2010;584(18):4115- 4120.
247. Srivastava N, Manvati S, Srivastava A., et al miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting anti-apoptotic gene BCL-2: a potential for therapeutic intervention. Breast Cancer Res. 2011; 13(2):R39.
248. Lal A, Navarro F, Maher C.A., et al miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless," 3'UTR microRNA recognition elements. Mol Cell. 2009;35(5):610-625.
249. Qin W, Shi Y, Zhao B., et al miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One. 2010;5(2):e9429.
250. Mishra PJ, Song B, Wang Y., et al MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One. 2009;4(12):e8445.
251. Fang L, Deng Z, Shatseva T., et al MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene. 2011;30(7):806-821.
252. Meng F, Glaser SS, Francis H, et al Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med. 2012;16(1):160-173.
253. Al-Nakhle H., Burns PA, Cummings M, et al Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res. 2010;70(11):4778-4784.
254. Manni I, Artuso S, Careccia S., et al The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J. 2009;23(11):3957-3966.
255. Hurst DR, Edmonds MD, Scott G.K., et al Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res. 2009;69(4):1279-1283.
256. Zhang CZ, Zhang JX, Zhang A.L., et al MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer. 2010;9:229.
257. Wurz K, Garcia RL, Goff B.A., et al MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer. 2010;49(7):577-584.
258. Wong QW, Ching AK, Chan A.W., et al MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res. 2010;16(3): 867-875.
259. Mercatelli N, Coppola V, Bonci D., et al The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One. 2008;3(12):e4029.
260. Visone R, Russo L, Pallante P., et al MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007;14(3):791-798.
261. le Sage C., Nagel R, Egan D.A., et al Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007;26(15):3699-3708.
262. Wu L, Cai C, Wang X., et al MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Lett. 2011;585(9):1322-1330.
263. Neves R, Scheel C, Weinhold S., et al Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res Notes. 2010;3:219.
264. Zhang S, Wu Y, Feng D., et al miR-145 inhibits lung adenocarcinoma stem cells proliferation by targeting OCT4 gene. Zhongguo Fei Ai Za Zhi. 2011;14(4):317-322.
265. Yin R, Zhang S, Wu Y., et al microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncol Rep. 2011;25(6):1747-1754.
266. Wu Y, Liu S, Xin H., et al Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer. 2011;117(17):3989-3998.
267. Kano M, Seki N, Kikkawa N., et al miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127(12):2804-2814.
268. Chen Z, Zeng H, Guo Y., et al MiRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 2010;29:151.
269. Schickel R, Park SM, Murmann A.E., et al miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell. 2010;38(6):908-915.
270. Ahmad A, Aboukameel A, Kong D., et al Phosphoglucose isomerase/ autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res. 2011;71(9):3400-3409.
271. Brabletz S, Bajdak K, Meidhof S., et al The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 2011;30(4):770-782.